Metraipolis › archive › dc_cfd315debece

Dapagliflozin in lupus nephritis: renal and hematologic outcomes from a randomized controlled trial — Europe PMC PMID:42549085

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42549085
DOI: 10.1093/ckj/sfag231
License (as archived): solo-consultazione
Archived: 2026-10-18T08:38:36.586Z
SHA-256 of the archived text: a44700373e5a57014afa7da259e1954ed8c691ac08231040545bcf6463d37ed3
Stable URL of this page: https://metraipolis.com/documento/dc_cfd315debece

How to cite

Dapagliflozin in lupus nephritis: renal and hematologic outcomes from a randomized controlled trial — Europe PMC PMID:42549085 — Europe PMC (en), https://europepmc.org/article/MED/42549085 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cfd315debece (Metraipolis archive dc_cfd315debece, sha256 a44700373e5a57014afa7da259e1954ed8c691ac08231040545bcf6463d37ed3)

BibTeX

@misc{dccfd315debece,
  title = {Dapagliflozin in lupus nephritis: renal and hematologic outcomes from a randomized controlled trial — Europe PMC PMID:42549085},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42549085},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cfd315debece; sha256 a44700373e5a57014afa7da259e1954ed8c691ac08231040545bcf6463d37ed3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42549085. Agents can read the archived copy with the MCP tool read_document.